| Literature DB >> 34158830 |
Arnab Mukherjee1,2, Meheli Chatterjee3,4, Shreshta Chattopadhyay1,5, Chitralekha Bhowmick1,2, Archisman Basu3,6, Surya Bhattacharjee7, Soumita Ghose8,9, Soumitra Shankar Datta1,10,11.
Abstract
BACKGROUND: Addressing the mental health needs of cancer patients and their caregivers improves the quality of care the patient receives in any cancer care ecosystem. International practice currently encourages integrated care for physical and mental health in oncology. The coronavirus disease (COVID-19) pandemic has affected the delivery of healthcare services across the world. The current research paper is on the psycho-oncology service provision for hospitalised cancer patients before and during the COVID-19 pandemic.Entities:
Keywords: COVID-19; SARS-CoV-2; cancer; oncology; psychiatry; psycho-oncology; psychological support
Year: 2021 PMID: 34158830 PMCID: PMC8183654 DOI: 10.3332/ecancer.2021.1226
Source DB: PubMed Journal: Ecancermedicalscience ISSN: 1754-6605
Figure 1.Trend of newly diagnosed cases of COVID-19 in the country and also among the hospital staff where the study was conducted.
Characteristics of hospitalised cancer patients who were referred to psycho-oncology services during a period of 1 month in pre-COVID pandemic times (in 2019) and during the peak of the COVID-19 pandemic (in 2020).
| Variable | 2019 | 2020 | |||
|---|---|---|---|---|---|
| ( | (%) | ( | (%) | ||
| Age (in years) | 51.5 (IQR 38.5 – 62) | 55 (IQR 46.25 – 64.25) | |||
| Gender | Female | 29 | 39.2 | 20 | 38.5 |
| Male | 45 | 60.8 | 32 | 61.5 | |
| Domicile | West Bengal | 51 | 68.9 | 41 | 78.8 |
| Bihar | 4 | 5.4 | 3 | 5.8 | |
| Jharkhand | 5 | 6.8 | 2 | 3.8 | |
| Orissa | 2 | 2.7 | 1 | 1.9 | |
| Other Indian states | 3 | 4.1 | 5 | 9.6 | |
| Bangladesh | 9 | 12.2 | 0 | 0 | |
| Educational level attained | No formal education | 10 | 13.5 | 14 | 26.9 |
| Primary school | 13 | 17.8 | 7 | 13.5 | |
| High school | 9 | 12.2 | 2 | 3.8 | |
| Graduation | 24 | 32.4 | 16 | 30.8 | |
| Post-graduation | 13 | 17.6 | 3 | 5.8 | |
| Other professional qualifications | 5 | 6.7 | 10 | 19.2 | |
| Occupation | Unemployed | 23 | 31.08 | 24 | 46.2 |
| Government employee | 4 | 5.4 | 5 | 9.6 | |
| Private company employee | 5 | 6.7 | 5 | 9.6 | |
| Businessman | 11 | 14.9 | 7 | 13.5 | |
| Professional (doctor, lawyer etc) | 7 | 9.4 | 2 | 3.8 | |
| Semi-skilled worker | 5 | 6.8 | 2 | 3.8 | |
| Homemaker | 9 | 12.2 | 5 | 3.8 | |
| Student | 10 | 13.5 | 2 | 3.8 | |
| Duration of hospitalisation (in days) | 10 (IQR 7–14.25) | 12 (IQR 7–22) | |||
| Cancer type | HNC | 27 | 36.5 | 28 | 53.8 |
| Breast cancer | 3 | 4.1 | 2 | 3.8 | |
| Lung cancer | 5 | 6.8 | 3 | 5.8 | |
| GI cancers | 11 | 14.9 | 6 | 11.5 | |
| Gynaecological cancers | 7 | 9.5 | 6 | 11.5 | |
| Urological cancers | 1 | 1.4 | 3 | 5.8 | |
| Haematological cancers | 18 | 24.3 | 4 | 7.7 | |
| Other cancers | 2 | 2.7 | 0 | 0 | |
| Co-morbidities (one person may have more than one co-morbidities) | Hypertension | 23 | 31.1 | 22 | 42.3 |
| Diabetes | 15 | 20.3 | 15 | 28.8 | |
| Hypothyroidism | 8 | 10.8 | 8 | 15.4 | |
| Others | 20 | 27 | 19 | 36.5 | |
| COVID status | Positive | NA | 7 | 13.5 | |
| Indeterminate | NA | 8 | 15.4 | ||
| Negative | NA | 37 | 71.2 | ||
| Admitting team | Surgical Oncology | 33 | 44.6 | 35 | 67.3 |
| Medical Oncology | 9 | 12.2 | 6 | 11.5 | |
| Clinical Haematology | 12 | 16.2 | 3 | 5.8 | |
| Others | 20 | 27 | 8 | 15.8 | |
| Reason for admission | Surgery | 31 | 41.9 | 34 | 65.4 |
| Chemotherapy | 9 | 12.1 | 3 | 5.7 | |
| Management of co-morbidities (including infections) | 22 | 29.7 | 5 | 9.6 | |
| GI symptoms (including intestinal obstructions) | 4 | 5.4 | 4 | 7.7 | |
| Symptom management (including pain) | 6 | 8.1 | 5 | 9.6 | |
| Pre-habilitation | 1 | 1.35 | 1 | 1.9 | |
| Organic brain syndrome | 1 | 1.35 | 0 | 0 | |
Psychiatric referral, response of psycho-oncology services and psychiatric diagnosis of hospitalised cancer patients who were referred to psycho-oncology services during a period of 1 month in pre-COVID pandemic times (in 2019) and during the peak of the COVID-19 pandemic (in 2020).
| Variable | 2019 | 2020 | |||
|---|---|---|---|---|---|
| Reasons for referral | Child and family assessment of paediatric cancer patients | 3 | 4.1 | 0 | 0 |
| Screening for emotional distress in post-operative period | 24 | 32.4 | 20 | 38.5 | |
| Sleep problems | 6 | 8.1 | 4 | 7.7 | |
| Symptoms of anxiety | 7 | 9.5 | 10 | 19.2 | |
| Low mood | 14 | 19 | 10 | 19.2 | |
| Pre-existing psychiatric disorder and on treatment | 3 | 4.1 | 5 | 9.6 | |
| Restlessness secondary to delirium | 9 | 12.2 | 1 | 1.9 | |
| Pre-habilitation | 1 | 1.4 | 1 | 1.9 | |
| Organic brain syndrome | 1 | 1.4 | 0 | 0 | |
| Not mentioned | 6 | 8.1 | 1 | 1.9 | |
| Assessment by consultant psychiatrist within | Same day | 74 | 100 | 44 | 84.6 |
| within 1 day | 3 | 5.8 | |||
| within 2 days | 3 | 5.8 | |||
| Within 1 week | 2 | 3.8 | |||
| Psychiatric diagnosis | Delirium | 13 | 17.6 | 5 | 9.6 |
| Adjustment disorder | 16 | 21.6 | 16 | 30.8 | |
| Depressive episode | 2 | 2.7 | 5 | 9.6 | |
| Anxiety disorders | 10 | 13.5 | 1 | 1.9 | |
| Substance related problems | 4 | 5.4 | 1 | 1.9 | |
| Organic mood disorder | 4 | 5.4 | 0 | ||
| Schizophrenia | 0 | 0 | 1 | 1.9 | |
| Other psychiatric disorder | 1 | 1.4 | 1 | 1.9 | |
| No psychiatric diagnosis | 24 | 32.4 | 22 | 42.3 | |
Anecdotal sources of stresses reported by patients and family members during the COVID-19 pandemic.
| Source of stress for cancer patients | Source of stress for family/caregivers of cancer patients | |
|---|---|---|
| Social construct of COVID-19 | 1. Some cancer patients were worried about contracting COVID-19 infection. | 1. Some family members were scared of supporting the patient due to fear of contracting COVID-19. |
| 2. If they contracted COVID-19 infection, during isolation, they were often reminded of their illness (cancer) and the usual sources of support were cut-off temporarily from them which was stressful. | ||
| Barriers to access oncology service | 1. Majority of the patients wanted to continue their cancer treatment. | 1. Family members found it difficult to commute to cancer centres due to the lock down in the early days. |
| 2. If for some reasons there were interruptions in their oncology treatment, this was a source of worry for them. | ||
| Treatment seeking and treatment adherence | 1. Several factors led to delay in treatment seeking for some of the patients who were newly diagnosed with cancer outside the hospital. | 1. Family members found it difficult to commute and care of the patients |
| Economic issues | 1. Economic hardships were felt by many patients. | 1. Overall economic hardships were felt by family members and caregivers as well. This is particularly important in many low and middle income countries (LMICs) where oncology treatment is often funded by out-of-pocket expenses of patients and his or her family members. |
| 2. Several patients were apprehensive of losing their job as they viewed cancer to be a major disadvantage in the milieu of the broader economic downturn. |
Psychological treatment details and psychotropic medication used for hospitalised cancer patients who were referred to psycho-oncology services during a period of 1 month in pre-COVID-19 pandemic times (in 2019) and during the peak of the COVID-19 pandemic (in 2020).
| Variable | 2019 | 2020 | |||
|---|---|---|---|---|---|
| ( | (%) | ( | (%) | ||
| Treatment given | Psychological treatment only | 15 | 20.3 | 12 | 23.1 |
| Medication only | 16 | 21.6 | 4 | 7.7 | |
| Both psychological and medication treatment | 23 | 31.1 | 17 | 32.7 | |
| None needed | 20 | 27 | 19 | 36.5 | |
| Type of psychological intervention | No psychological intervention | 21 | 28.4 | 19 | 36.5 |
| Psychoeducation | 9 | 12.2 | 3 | 5.8 | |
| Allowing to express worries/ventilation | 8 | 10.8 | 9 | 17.3 | |
| Sleep hygiene | 4 | 5.4 | 5 | 9.6 | |
| Providing support to the family | 5 | 6.8 | 2 | 3.8 | |
| Supportive therapy to patient | 14 | 18.9 | 10 | 19.2 | |
| Environmental modification | 13 | 17.6 | 4 | 7.7 | |
| Number of psychotropic medications prescribed | None | 37 | 50 | 31 | 59.6 |
| One | 30 | 40.5 | 17 | 32.7 | |
| Two | 7 | 9.5 | 4 | 7.7 | |
| Classification of daily dosage according to British National Formulary (BNF) [Same patient may be on more than one medication] | Therapeutic range | 20 | 48.8 | 12 | 48 |
| Responded below therapeutic range | 21 | 51.2 | 13 | 52 | |
| Needed medication above therapeutic range | 0 | 0 | 0 | 0 | |
| Medications prescribed (Same patient may have been prescribed more than one medication) | Escitalopram | 1 | 2.4 | 1 | 4 |
| Sertraline | 3 | 7.3 | 0 | 0 | |
| Mirtazapine | 3 | 7.3 | 4 | 16 | |
| Aripiprazole | 11 | 26.8 | 2 | 8 | |
| Olanzapine | 7 | 17.1 | 1 | 4 | |
| Risperidone | 6 | 14.6 | 3 | 12 | |
| Lorazepam | 3 | 7.3 | 2 | 8 | |
| Clonazepam | 5 | 12.2 | 11 | 44 | |
| Alprazolam | 1 | 2.4 | 1 | 4 | |
| Zolpidem | 1 | 2.4 | 0 | 0 | |
Figure 2.Challenges and possible solutions for providing psychological interventions to cancer patients during the COVID-19 pandemic.
Figure 3.Comparative bed occupancy rates of the institution.
Figure 4.Comparative clinical activity in 2019 and 2020.
Figure 5.Training sessions for staff during the pandemic.